DPP4 inhibitors and GLP-1 receptor agonists, i.e., derivatives rendered less sensitive to cleavage by DPP4, have thus become two important classes of drugs for the management of type II diabetes and obesity (Deacon, 2019; Palmer et al, 2016). Here, GLP1R is linked to Obesity.